Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.

SERVICIO

Financiamiento, deuda y mercados de capitales

PARTES

Contáctese con el equipo de la transacción

Geoff Nash

Partner

Londres, Reino Unido
Oaklins Cavendish

Ver perfil Contáctenos

Transacciones relacionadas

SHS has sold Spiegelberg to Luciole Medical AG

Private Equity | Salud

SHS has sold Spiegelberg to Luciole Medical AG

SHS and a minority co-shareholder have sold Spiegelberg GmbH to Luciole Medical AG.

Ecorobotix has completed a fundraising

Agricultura | Automotriz | Maquinaria y Componentes Industriales | TMT

Ecorobotix has completed a fundraising

Ecorobotix has raised US$52 million. The new capital will enable the company to grow into new markets, expand its product range and build on the existing commercial success of ARA in Europe.

Presmed Australia has been acquired by ICG

Private Equity | Salud

Presmed Australia has been acquired by ICG

Advanced Health Limited has sold Presmed Australia Pty Ltd (PMA) to ICG.